MetaCap

Ernexa Therapeutics Inc. (ERNA)

NASDAQ: ERNAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.36-0.27 (-16.56%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ERNA stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$11.22
52-week range
1.35 – 37.50
Day range
1.35 – 1.60
Volume / Avg
20.38K / 43.90K
Beta
—

52-week range

$1.35$37.50

ERNA stock today

Shares of Ernexa Therapeutics (ERNA) finished lower on Nov 20 at $1.36, a drop of 16.56% or $0.27 per share, versus the S&P 500's 3.70% decline. Trading was light, with 20.38K shares changing hands, about 46% of the average daily volume. At this level, ERNA sits near the bottom of its 52-week range of $1.35 to $37.50: 96.4% below the high and 0.7% above the low.

Ernexa Therapeutics has posted a net loss over the last twelve months (EPS of -$11.22), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Ernexa Therapeutics

Company profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Sanjeev Luther
Headquarters
Cambridge, MA
Employees
5

Financial highlights

Full financials

Ernexa Therapeutics reported a net loss of $14.1 million, compared with a loss of $44.5 million a year earlier. Diluted earnings per share came in at -$2.24.

Ernexa Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—$582.00K$68.00K$0—
Growth—+755.88%———
Net income$-14.08M$-44.54M$-21.67M$-24.58M$-122.55M
EPS (diluted)$-2.24$-48.96$-4.08$-8.06$-56.61

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$30.00+2105.88%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 6, 2026
EPS actual vs est.
$-1.89 vs $-3.84
Surprise
+50.78%

ERNA news

All ERNA news

Ernexa Therapeutics peers

Health Care sector
ERNA peer companies
CompanyPrice% ChgMarket capCompare
HCWBHCW Biologics Inc.0.7491+1.90%$2.35Mvs ERNA
ONCOOnconetix Inc.2.89-8.54%$2.37Mvs ERNA
LABTLakewood-Amedex Biotherapeutics Inc.0.2449+15.03%$2.19Mvs ERNA
GRIGRI Bio Inc.1.120.00%$2.45Mvs ERNA
RDHLRedhill Biopharma Ltd. ADR0.281-13.08%$2.50Mvs ERNA
SXTP60 Degrees Pharmaceuticals Inc.0.4682-6.36%$2.10Mvs ERNA
DRMADermata Therapeutics Inc.0.5095-4.23%$2.51Mvs ERNA
KAPAKairos Pharma Ltd.0.4359-4.62%$2.04Mvs ERNA

Indexes, lists and sector

Ernexa Therapeutics stock FAQ

What is Ernexa Therapeutics's stock price today?

ERNA last traded at $1.36 as of Nov 20, 4:00 PM EST, down 16.56% on the day. Prices are delayed at least 15 minutes.

Who is Ernexa Therapeutics's CEO?

Mr. Sanjeev Luther is the chief executive officer of Ernexa Therapeutics Inc., which has about 5 employees.

What is the ERNA 52-week high?

The 52-week high for ERNA is $37.50 and the 52-week low is $1.35. The stock is currently 96.4% below its high.

Compare ERNA